[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-reported-outcomes-pro\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-reported-outcomes-pro":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,89,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100641124","do-immediate-digital-workflows-increase-patient-value-100641124",false,"NCT07656597","Do Immediate Digital Workflows Increase Patient Value?","Do Immediate Digital Workflows Increase Patient Value? A Patient-Reported Outcome Measure-Based Randomized Controlled Trial Comparing Immediate Versus Delayed Digital Posterior Implant Workflows","ITI PROM RCT","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Indication for single implant therapy in a posterior premolar or molar extraction site.\n* Good oral hygiene with FMPS ≤20%.\n* Controlled periodontitis according to protocol definition.\n* At least one natural tooth adjacent to the implant site and presence of an antagonist tooth.\n* Ability to comply with study procedures and provide written informed consent.\n* Adequate bone volume for immediate or delayed placement.\n* Extraction site suitable for centrally positioned, prosthetically driven implant placement using straight prosthetic components.\n* Ability to achieve 3-4 mm circumferential implant engagement in native bone along the planned implant axis while maintaining safety distance from vital structures.\n* For molar sites, septal bone classified as Smith \\& Tarnow Type A or Type B, including cases requiring closed sinus floor elevation.\n* Post-extraction socket presenting as a contained or partially contained defect with at least three relatively intact socket walls and no individual socket wall vertical defect \\>5 mm.\n* No facial soft-tissue dehiscence or mucogingival defect associated with buccal bone dehiscence.\n\nExclusion Criteria:\n\n* • Known or suspected poor compliance, alcohol abuse, or substance abuse.\n\n  * Systemic or local contraindications to implant surgery.\n  * History of head\u002Fneck radiotherapy or recent malignancy within 5 years.\n  * Use of medications affecting bone metabolism.\n  * Bisphosphonate use within the past 5 years.\n  * Uncontrolled periodontal disease.\n  * Heavy smoking (\\>10 cigarettes\u002Fday).\n  * Pregnancy or lactation.\n  * Teeth with periapical lesions \\>5 mm in greatest diameter, or sockets demonstrating a large cortical perforation \\>5 mm in greatest dimension on CBCT.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This two-center randomized controlled trial will evaluate whether an immediate digital posterior implant workflow provides greater patient-defined value than a delayed digital workflow in adults requiring single posterior implant rehabilitation. Participants will be randomized 1:1 to immediate implant placement at the time of tooth extraction or to delayed implant placement after approximately 16 weeks of healing following extraction and ridge preservation as indicated. The primary endpoint is oral health-related quality of life assessed longitudinally using the OHIP-14 questionnaire and analyzed as the model-based mean score averaged across the active treatment phase from baseline through definitive crown delivery. Secondary outcomes include workflow-related patient experience, chairside time, number of visits, postoperative pain, buccal contour changes based on intraoral scan-derived volumetric analysis, radiographic marginal bone level changes, implant survival, clinical peri-implant parameters, technical complications, esthetic outcomes, accuracy of guided implant placement, and clinician-reported workflow outcomes.",[27,28,29,30,31,32,33],"Dental Implant","Implant Therapy","Immediate Dental Implant Placement","Delayed Implant","Guided Surgery Accuracy","Patient-Reported Outcomes (PRO)","Single Tooth Dental Implant",[27,35,36,37,38,39,40,41,42,43],"immediate implant placement","delayed implant placement","digital workflow","guided surgery","patient-reported outcomes","OHIP-14","posterior implant rehabilitation","chairside time","volumetric analysis","NOT_YET_RECRUITING","2026-06-15",{"date":47,"type":48},"2026-06-18","ACTUAL",{"date":50,"type":21},"2026-08-03",{"date":52,"type":21},"2028-10-31",{"name":54,"class":55},"Heinrich-Heine University, Duesseldorf","OTHER",2,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100603065","symptoms-burden-in-lung-cancer-patients-undergoing-definitive-chemoradiotherapy-insights-from-electronic-patient-reported-outcomes-100603065","NCT07131670","Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","ePRO-LC-CRT","Inclusion Criteria:\n\n* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC\n* Age ≥ 18 years\n* Receiving definitive chemoradiotherapy\n* Able and willing to complete electronic questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe comorbidities (heart, liver, kidney)\n* Psychiatric illness or cognitive impairment\n* Prior chest or mediastinal radiotherapy",{"count":66,"type":21},100,"OBSERVATIONAL","This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.",[70,71,32],"Lung Cancer","Chemoradiotherapy",[73,74,75,76,70,77],"Symptom Burden","Symptom Clusters","Electronic Patient-Reported Outcomes","MDASI-LC","EQ-5D","RECRUITING","2025-08-12",{"date":81,"type":48},"2025-08-20",{"date":83,"type":48},"2024-06-01",{"date":85,"type":21},"2026-03-31",{"name":87,"class":55},"Qian Chu",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":67,"phases":4,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":88},"100602271","smc-radiation-oncology-sabr-cohort-for-oligometastasis-100602271","NCT07121335","SMC Radiation Oncology SABR Cohort for Oligometastasis","Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer","SABR-OMOP","Inclusion Criteria:\n\n* Performance status (ECOG PS) 0-2\n* Diagnosed with metastatic disease\n* Confirmed to have oligometastatic\u002Foligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)\n\nExclusion Criteria:\n\n* Patient with a history of prior radiotherapy to the site planned for SABR\n* Patients with concomitant brain metastases",{"count":98,"type":21},60,"3 Years","The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.\n\nThe main questions it aims to answer are:\n\n1. oncologic outcomes (progression-free survival, local failure rate),\n2. patient-reported outcomes,\n3. physician-assessed toxicity, and\n4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.",[102,103,104,105,32],"Stereotactic Body Radiation Therapy (SBRT)","Oligometastasis","Oligoprogression","ctDNA",[107,103,104,105],"Stereotactic body radiotherapy","2025-08-08",{"date":110,"type":48},"2025-08-13",{"date":112,"type":48},"2025-05-01",{"date":114,"type":21},"2030-03-31",{"name":116,"class":55},"Samsung Medical Center",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":88},"100587482","a-patient-portal-and-proms-to-improve-health-problem-detection-and-retention-in-hiv-care-the-drhive-study-100587482","NCT06928961","A Patient Portal and PROMs to Improve Health Problem Detection and Retention in HIV Care: The DRHIVe Study","Implementation of a Patient Portal and Tailored Patient-Reported Outcome Measures to Improve Health Problem Detection and Retention in HIV Care: The DRHIVe Study","Inclusion Criteria:\n\n* Confirmed living with HIV\n* Adult (at least 18 years old)\n* Literate in English or French\n* Patient at the study site\n\nExclusion Criteria:\n\n* Cognitive impairment or medical instability that prevents participation\n* Insufficient mastery of French or English to participate (e.g., complete PROMs, study questionnaires)",{"count":125,"type":21},360,[24],"Too often, people living with HIV (PLHIV) face challenges, including additional health and psychosocial problems, that complicate self-care, like medication-taking and medical appointment attendance. Healthcare providers are not always aware when patients face these difficulties. A 'patient portal' is an online application that can give patients access to their medical records, appointment reminders, and questionnaires to inform providers about their health and wellbeing. Patient portals in HIV care can help providers detect patient problems and improve care. At the McGill University Health Centre's (MUHC) HIV care service, a survey showed great interest in a patient portal among both PLHIV and healthcare providers. Yet, little is known on how best to integrate a portal in HIV care settings and ensure it is accessible to patients. This project will be conducted at the MUHC's HIV care service in Montreal, Quebec which has over 2,000 patients. Participating patients will log on to a patient portal through a smartphone application and have a calendar of their HIV care appointments, health questionnaires to complete (previously chosen by people with HIV and healthcare providers), reminders for both and access to educational material. HIV physicians will be able to see their patients' questionnaire results to discuss them during clinic appointments. The project's objectives are to better understand what is needed to successfully integrate a portal in similar HIV practices with diverse patients and learn how acceptable and usable it is for HIV patients and doctors. The project will also examine how patient portal use impacts satisfaction, attendance, and physician detection of specific health problems. Furthemore, it will consider how patient sex, age, and ethnicity influence the results. People with HIV, providers, and staff at the study site will be involved in decision-making about this project. Over its 5-year duration, knowledge will be gained and shared on how to expand portal use efficiently and equitably in similar HIV care centers.",[129,32,130,131],"HIV","Screening","Patient Portals",[129,133,134,135,136,130,137,138,139,140,141,142],"Implementation","mHealth","Patient-reported outcome measures","PROMs","Patient portal","Mixed methods","Stakeholder engagement","Quebec","Canada","HIV care","2025-04-08",{"date":145,"type":48},"2025-04-15",{"date":147,"type":21},"2025-12",{"date":149,"type":21},"2029-12",{"name":151,"class":55},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]